Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | qIP-MS in high-risk myeloma patients in the GEM-CESAR trial

Noemí Puig • 23 Jun 2020
EHA 2020
Multiple Myeloma Rare Diseases Smoldering Myeloma Carfilzomib Dexamethasone Lenalidomide Melphalan
GEM-CESAR

Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, discusses the use of quantitative immunoprecipitation mass spectrometry (QIP-MS) as a measure of minimal residual disease (MRD) in high-risk smoldering myeloma patients enrolled in the GEM-CESAR study (NCT02415413). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Noemí Puig

1:02
Challenges associated with developing a standardized technique for MRD detection in myeloma
Noemí Puig • 29 Sep 2023
2:37
Evidence supporting MRD-guided treatment breaks in MM
Noemí Puig • 29 Sep 2023
1:20
Using mass spectrometry & NGF to analyze MRD negativity & long-term disease control in NDMM
Noemí Puig • 29 Sep 2023
4:02
The diagnostic and prognostic value of mass spectrometry in multiple myeloma
Noemí Puig • 13 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals